ASH 2024 | Real-world evidence of the efficacy of CPX-351 in secondary AML
Fabio Guolo, MD, University of Genoa, Genoa, Italy, comments on the real-world efficacy of CPX-351 in secondary acute myeloid leukemia (AML), as defined by the WHO 2022 classification. The study found no significant difference in complete response (CR) rates and survival outcomes between the real-world and clinical trial settings. Dr Guolo also mentions that, when compared with historical data from patients treated with an intensified fludarabine regimen, CPX-351 showed improved responses and reduced toxicity. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We studied how the patient in the real world responds to CPX because most patients that will receive CPX are patients with secondary AML and those are elderly patients with AML secondary sometimes to other neoplasms so most of them would not be eligible to clinical trials. So we wanted to see in the real world how they do, if it’s any way different from the clinical trial that led to the approval of the drug...
We studied how the patient in the real world responds to CPX because most patients that will receive CPX are patients with secondary AML and those are elderly patients with AML secondary sometimes to other neoplasms so most of them would not be eligible to clinical trials. So we wanted to see in the real world how they do, if it’s any way different from the clinical trial that led to the approval of the drug. What we saw is that in the real world there is no difference from what was observed in the clinical trial both in terms of CR rate and survival, and then we compared with our historical data with intensified fludarabine treatment for secondary AML and what we saw is that with CPX we got more responses and less toxicities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
